贝美替尼(Binimetinib,Mektovi)
摘要
<正>贝美替尼是由艾瑞制药(Array BiopharmaInc.)研发的一种丝裂原活化蛋白激酶1/2(MEK1/MEK2)抑制剂,商品名为Mektovi(MEK162)。美国食品药品监督管理局(FDA)于2018年6月27日批准Braftovi胶囊与Mektovi片剂联合用药,用于治疗具有BRAFV600E或BRAFV600K突变的不可切除或转移性黑素瘤。艾瑞生物制药于2010年4月授权诺华制
引文
[1] US FDA.FDA approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations[BE/OL].[2018-07-05].https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm611981.htm.
[2] ELI M W,JOSEPH P L,BRIAN T H,et al.N3 alkylated benzimidazole derivatives as MEK inhibitors: WO,2003077914[P].2003-09-25.
[3] KIM T,AMARIA R N,SPENCER C,et al.Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma[J].Cancer Biol Med,2014,11(04):237-246.
[4] TROIANI T,VECCHIONE L,MARTINELLI E,et al.Intrinsic resistance to selumetinib,a selective inhibitor of MEK1/2,by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells[J].Br J Cancer,2012,106(10):1648-1659.
[2] ELI M W,JOSEPH P L,BRIAN T H,et al.N3 alkylated benzimidazole derivatives as MEK inhibitors: WO,2003077914[P].2003-09-25.
[3] KIM T,AMARIA R N,SPENCER C,et al.Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma[J].Cancer Biol Med,2014,11(04):237-246.
[4] TROIANI T,VECCHIONE L,MARTINELLI E,et al.Intrinsic resistance to selumetinib,a selective inhibitor of MEK1/2,by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells[J].Br J Cancer,2012,106(10):1648-1659.